Greifswald, 01/04/2021 - Cheplapharm acquires the global rights for the products Atacand® and Atacand® Plus
CHEPLAPHARM has held the rights for Atacand® and Atacand® Plus in 28 European markets since 2018. In autumn last year CHEPLAPHARM agreed with AstraZeneca to also acquire the global rights (excluding the US) for these two products and the deal was closed successfully during the last week of December 2020.
Atacand® (Candesartan Cilexetil) is a prescription medication used to treat heart failure and high blood pressure. The product was developed in collaboration between AstraZeneca and Takeda and first launched in 1997. AstraZeneca and CHEPLAPHARM agreed that AstraZeneca will continue to manufacture and supply Atacand® and Atacand® Plus and will continue to commercialise the medicines in the relevant territories during a three-year transition period. The transfer of the marketing authorizations and integration of the product into the manufacturing and distribution network of CHEPLAPHARM is therefore expected to be finalised three years after closing. AstraZeneca received a payment of USD 250m on closing and will receive non-contingent payments of USD 100m and USD 50m in the first half of 2021.
“We have planned to take over the global rights for Atacand® since 2018 and are proud that it is now finally taking place,” said CHEPLAPHARM´s CEO Sebastian F. Braun.*m/w/d